Document:

Exhibit 10.1

                       EXCLUSIVE DISTRIBUTORSHIP AGREEMENT

This Exclusive Distributorship Agreement ("Agreement"), made and effective this
1st day of November 2007 by and between Galea Life Sciences, Inc., A Florida
Corporation ("Manufacturer") and Allion Healthcare, Inc. ("Distributor").

Manufacturer desires to appoint Distributor, and Distributor desires to accept
appointment, as an exclusive distributor of Manufacturer's products within a
defined area as set forth herein.

NOW, THEREFORE, in consideration of the mutual agreements promises set forth
herein, the parties agree as follows:

1. RIGHTS GRANTED.

Manufacturer hereby grants to Distributor the exclusive right, on the terms and
conditions contained herein, to purchase, inventory, promote and resell
"Manufacturer's Products" (as defined below) within the following area (the
"Territory"): Unites States of America.

2. PRODUCTS.

As used in this Agreement, the term "Manufacturer's Products" shall mean
Nutraplete Immune System Formula.

3. TERMS OF SALE.

All sales of Manufacturer's Products to Distributor shall be made pursuant to
this Agreement at such prices and on such terms as Manufacturer shall establish
from time to time on at least thirty (30) days notice. All prices are FOB
Manufacturer's plant. Manufacturer agrees to properly pack all items for
shipment. Risk of loss due to damage or destruction of Manufacturer's Products
shall be borne by Distributor after delivery to the carrier for shipment. The
shipper will be selected by Manufacturer unless Distributor requests a
reasonable alternative. All orders are subject to acceptance by Manufacturer.
Except as otherwise expressly agreed by Manufacturer in advance, this Agreement
shall control all aspects of the dealings between Manufacturer and Distributor
with respect to the Manufacturer's Products and any additional or different
terms in any Distributor order are hereby rejected.

4. MARKETING POLICIES.

Distributor will at all times maintain adequate inventories of Manufacturer's
Products, and assist the Manufacturer in appropriately promoting the product
including helping the Manufacturer arrange clinical evaluations or studies of
the Manufacturer's Products.

<PAGE>

5.   INDEMNIFICATION.

A. Manufacturer agrees to protect Distributor and hold Distributor harmless from
any loss or claim arising out of inherent defects in any of Manufacturer's
Products existing at the time such product is sold by Manufacturer to
Distributor, provided that Distributor gives Manufacturer immediate notice of
any such loss or claim and cooperates fully with Manufacturer in the handling
thereof.

B. Distributor agrees to protect Manufacturer and hold Manufacturer harmless
from any loss or claim arising out of the negligence of Distributor,
Distributor's agents, employees or representatives in the installation, use,
sale or servicing of Manufacturer's Products or arising out of any
representation or warranty made by Distributor, its agents, employees or
representations with respect to Manufacturer's Products that exceeds
Manufacturer's limited warranty. Further, in the event that any of Distributor's
dealers shall, with respect to any of Manufacturer's Products purchased from
Distributor, fail to discharge the dealer's obligations to the original consumer
pursuant to the terms and conditions of Manufacturer's product warranty and
consumer service policies, Distributor agrees to discharge promptly such
unfulfilled obligations.

6.   ORDER PROCESSING AND RETURNS.

A. Manufacturer will employ its best efforts to fill Distributor's orders
promptly on acceptance, but reserves the right to allot available inventories
among distributors at its discretion.

B. Except for Manufacturer's products that are defective at the time of sale to
Distributor, Manufacturer shall not be obligated to accept any of Manufacturer's
Products that are returned. In the event such returns are accepted, Manufacturer
may impose a reasonable restocking charge.

7.   FINANCIAL POLICIES.

Distributor acknowledges the importance to Manufacturer of Distributor's sound
financial operation and Distributor expressly agrees that it will:

A. Maintain and employ in connection with Distributor's business and operations
under this Agreement such working capital and net worth as may be required to
enable Distributor properly and fully to carry out and perform all of
Distributor's duties, obligations and responsibilities under this Agreement;

B. Pay promptly all amounts due Manufacturer in accordance with terms of sale
extended by Manufacturer from time to time;

In addition to any other right or remedy to which Manufacturer may be entitled,
shipments may be suspended at Manufacturer's discretion in the event that
Distributor fails to promptly and faithfully discharge each and every obligation
in this Section.

<PAGE>

8.  USE OF MANUFACTURER'S NAME.

Distributor shall not contest the right of Manufacturer to exclusive use of any
trademark or trade name used or claimed by Manufacturer. Distributor may,
subject to Manufacturer's policies regarding reproduction of same, utilize
Manufacturer's name, trademarks or logos in advertising on stationery and
business cards, without written permission.

9.  RELATIONSHIP OF THE PARTIES.

The relationship between Manufacturer and Distributor is that of vendor and
vendee. Distributor, its agents and employees shall, under no circumstances, be
deemed employees, agents or representatives of Manufacturer. Distributor will
not modify any of Manufacturer's Products without written permission from
Manufacturer. Neither Distributor nor Manufacturer shall have any right to enter
into any contract or commitment in the name of; or on behalf of the other, or to
bind the other in any respect whatsoever.

10.  TERM AND TERMINATION.

Unless earlier terminated as provided below, the term of this Agreement shall
commence November 1, 2007 and shall continue until October 31, 2012. At the end
of the term, the Agreement shall continue until terminated by either party on at
least ninety (90) days prior notice.

A. Manufacturer may terminate at any time by written notice given to Distributor
not less than ninety (90) days prior to the effective date of such notice in the
event Manufacturer decides to terminate all outstanding distributor agreements
for Manufacturer's Products and to offer a new or amended form of distributor
agreement.

B. Manufacturer may terminate this Agreement upon notice to Distributor, upon
any of the following events: (1) failure of Distributor to fulfill or perform
any one of the duties, obligations or responsibilities of Distributor in this
Agreement, which failure is not cured with ten (10) days notice from
Manufacturer; (2) any assignment or attempted assignment by Distributor of any
interest in this agreement or delegation of Distributors obligations without
Manufacturer's written consent; (3) any sale, transfer or relinquishment,
voluntary or involuntary, by operation of law or otherwise, of any material
interest in the direct or indirect ownership or any change in the management of
Distributor; (4) failure of Distributor for any reason to function in the
ordinary course of business; (5) conviction in a court of competent jurisdiction
of Distributor, or a manager, partner, principal officer or major stockholder of
Distributor for any violation of law tending, in Manufacturer's opinion, to
affect adversely the operation or business of Distributor or the good name,
goodwill, or reputation of Manufacturer, products of Manufacturer, or

<PAGE>

Distributor; or (6) submission by Distributor to Manufacturer of false or
fraudulent reports or statements, including, without limitation, claims for any
refund, credit, rebate, incentive, allowance, discount, reimbursement or other
payment by Manufacturer.

11. OBLIGATIONS ON TERMINATION.

On termination of this Agreement, Distributor shall cease to be an authorized
distributor of Manufacturer and:

A. All amounts owing by Distributor to Manufacturer shall, notwithstanding prior
terms of sale, become immediately due and payable;

B. All unshipped orders shall be cancelled without liability of either party to
the other;

C. Distributor will resell and deliver to Manufacturer on demand, free and clear
of liens and encumbrances, such of Manufacturer's Products and materials bearing
Manufacturer's name as Manufacturer shall elect to repurchase, at a mutually
agree price, but not in excess of Manufacturer's current price to distributors
for such products and materials, provided that Manufacturer shall not be
obligated to pay Distributor for any item originally provided free of charge;
and

D. Neither party shall be liable to the other because of such termination for
compensation, reimbursement or damages on account of the loss of prospective
profits or anticipated sales, or on account of expenditures, investments, lease
or commitments in connection with the business or goodwill of Manufacturer or
Distributor or for any other reason whatsoever growing out of such termination.

12.  USE OF NAME PROHIBITED.

On termination of this Agreement, Distributor will remove and not thereafter use
any sign containing any trade name, logo or trademark of Manufacturer including,
but not limited to, "Nutraplete", and will immediately destroy all stationery,
advertising matter and other printed matter in its possession or under its
control containing such name, or any of Manufacturer's trademarks, trade names
or logos. Distributor will not at any time after such termination use or permit
any such trademark, trade name or logo to be used in any manner in connection
with any business conducted by it or in which it may have an interest, or
otherwise whatsoever as descriptive of or referring to anything other than
merchandise or products of Manufacturer. Regardless of the cause of termination,
Distributor will immediately take all appropriate steps to remove and cancel its
listings in telephone books, and other directories, and public records, or
elsewhere that contain the Manufacturer's name, logo or trademark. If
Distributor fails to obtain such removals or cancellations promptly,

<PAGE>

Manufacturer may make application for such removals or cancellations on behalf
of Distributor and in Distributor's name and in such event Distributor will
render every assistance.

13.  ACKNOWLEDGMENTS.

Each party acknowledges that no representation or statement, and no
understanding or agreement, has been made, or exists, and that in entering into
this Agreement each party has not relied on anything done or said or on any
presumption in fact or in law, (1) with respect to this Agreement, or to the
duration, termination or renewal of this Agreement, or with respect to the
relationship between the parties, other than as expressly set forth in this
Agreement; or (2) that in any way tends to change or modify the terms, or any of
them, of this Agreement or to prevent this Agreement becoming effective; or (3)
that in any way affects or relates to the subject matter hereof. Distributor
also acknowledges that the terms and conditions of this Agreement, and each of
them, are reasonable and fair and equitable.

14.  ENTIRE AGREEMENT.

This Agreement terminates and supersedes all prior understandings or agreements
on the subject matter hereof. This Agreement may be modified only by a further
writing that is duly executed by both parties.

15.  ASSIGNMENT.

Neither this Agreement nor any interest in this Agreement may be assigned by
Distributor without the prior express written approval of Manufacturer, which
may be withheld by Manufacturer at Manufacturer's absolute discretion.

16.  NO IMPLIED WAIVERS.

Except as expressly provided in this Agreement, waiver by either party, or
failure by either party to claim a default, of any provision of this Agreement
shall not be a waiver of any default or subsequent default.

17.  NOTICES

Any notice required by this Agreement or given in connection with it, shall be
in writing and shall be given to the appropriate party by personal delivery or
by certified mail, postage prepaid, or recognized overnight delivery services.

<PAGE>

If to Manufacturer:

Galea Life Sciences
c/o Jonathan Leinwand
101 NE 3rd Ave., Suite 1500
Fort Lauderdale, FL 33301

If to Distributor:

18.  GOVERNING LAW.

This Agreement shall be construed and enforced in accordance with the laws of
the state of Florida USA.

19.  SEVERABILITY.

If any term of this Agreement is held by a court of competent jurisdiction to be
invalid or unenforceable, then this Agreement, including all of the remaining
terms, will remain in full force and effect as if such invalid or unenforceable
term had never been included.

20.  HEADINGS.

Headings used in this Agreement are provided for convenience only and shall not
be used to construe meaning or intent.

         IN WITNESS WHEREOF, the parties have executed this Agreement as of the
date first above written.

Galea Life Sciences, Inc.                   Allion Healthcare Inc.

By: /s/ Paul Zuromski                       By: /s/ Michael Moran
   ---------------------------                 ---------------------------
   Paul Zuromski, President                    Michael MoranTHE GENERAL HOSPITAL CORPORATION
                            CLINICAL TRIAL AGREEMENT
                            (Investigator-Initiated)

       This Clinical Trial Agreement ("Agreement") is made as of the 28 day of
September, 2009 ("Effective Date") between CytoDyn, Inc., a publicly traded
corporation organized under the laws of Colorado with its principal place of
business at 1511 Third Street, Santa Fe, New Mexico 87505 ("Company"), and The
General Hospital Corporation d/b/a Massachusetts General Hospital, a
not-for-profit corporation organized under the laws of Massachusetts with its
principal place of business at 55 Fruit Street, Boston, MA 02114
("Institution"), each referred to herein individually as a "Party" and
collectively as the "Parties."

       The Parties to this Agreement share a common mission of improving the
public health by engaging in research for the purpose of discovering and making
available to the public new and improved medical drugs, devices, procedures, and
information. In connection with this mission, Institution, through Eric
Rosenberg, M.D. ("Principal Investigator"), having particular expertise and
opportunity, proposes to provide, and Company desires to have, further research
conducted on Company's drug described below.

       Accordingly, for good and valuable consideration, the sufficiency of
which is hereby acknowledged, the Parties agree as follows:

Section 1: Study Performance
----------------------------

       1.1    Conduct of Study in Accordance with Protocol; Priority of Terms.
Subject to the initial and continuing approvals described in Section 1.2 below,
Institution, through Principal Investigator, agrees to conduct an ex-vivo study
of Cytolin(R) brand of S6FI monoclonal antibodies ("Study Drug") in accordance
with the study protocol entitled "An observational study to determine the
in-vitro immunologic and virology activity of Cytolin," attached to this
Agreement as Exhibit A and herein incorporated by reference ("Study"). The
Parties agree that the Study will be performed in strict accordance with the
Study protocol entitled above, and any subsequent amendments thereto (the" Study
Protocol"). In the event of any conflict between the Protocol and the provisions
of the main body of this Agreement, the Protocol shall govern with respect to
scientific and subject consent issues, and the provisions of the main body of
this Agreement shall govern with respect to all other issues. In the event of
any conflict between the Study informed consent form and the provisions of this
Agreement with respect to any commitment by Company to cover costs associated
with subject injuries, the broader commitment (the commitment that is more
protective of human subjects) shall control.

       1.2    Study Review and Approvals. The Study shall be conducted by
personnel, agents, vendors, or consultants of Institution under the direction of
the Principal Investigator at Institution or additional facilities with the
prior approval and ongoing review of all appropriate and necessary review
authorities. Institution, through Principal Investigator, shall provide Company
with written evidence of review and approval of this Study by Institution's
Institutional Review Board ("IRB") prior to the initiation of the Study and
shall inform Company of the IRB's continuing reviews of the Study promptly after
each such review takes place, which shall be at least once per year. Initiation
of the Study Protocol shall not begin until IRB approval

<PAGE>

is obtained. In accordance with the obligations under the Food and Drug
Administration Amendment Act of 2007 ("the Act"), Company agrees to fully
register this Study with the public registry clinicaltrials.gov before
enrollment of the first patient at Institution and comply with all of the Act's
requirements thereafter.

       1.3    Completion of the Study. For purposes of this Agreement, Company
and Institution shall consider the Study to be complete and concluded at all
sites at such time as the occurrence of final data lock or earlier termination
by a Data Safety Monitoring Board or as otherwise specified in the Protocol
("Study Conclusion").

       1.4    Provision and Use of Study Drug. Company shall be responsible for
providing and delivering to Institution, at no charge, such quantities of the
Study Drug in bags for in vitro use as needed for conducting the Study in
accordance with the Study Protocol, along with the results of safety testing for
the lot of Study Drug provided, and conducted according to currently published
standards. Institution acknowledges receipt of the latter. Company understands
that Institution and Principal Investigator are relying on timely delivery of
the Study Drug in order for Institution to perform its obligations under this
Agreement. Institution understands that the ability of the Company to provide
the drug depends upon Institution providing shipping and delivery requirements.
Institution, through Principal Investigator, will safeguard such Study Drug with
the degree of care used for its own property and shall return or otherwise
dispose of any remaining Study Drug at the Study Conclusion in accordance with
the Study Protocol. Institution and Principal Investigator shall not use any
Study Drug for any purpose other than the Study, unless otherwise agreed.
Company represents and warrants that it is in compliance with federal, state,
and local laws and regulations relating to the manufacture and formulation of
any investigational drug and to other materials supplied, and with other
applicable legal requirements.,

       1.5    Compliance with Applicable Laws and Regulations. Parties agree to
conduct the Study in accordance with all applicable local, state, and federal
laws and regulations.

Section 2: Material Subject Information
---------------------------------------

       2.1    Company agrees to notify Principal Investigator in writing
promptly and at least within fifteen (15) days of information (such as Study
results) that could affect the safety or medical care of current or former
subjects, affect current subjects' willingness to continue participation,
influence the conduct of the Study, or alter the IRB's approval. Company and
Institution shall comply with their respective reporting requirements to
regulatory authorities, including, for example, the Food and Drug
Administration, the Office for Human Research Protections, and other authorities
as required. Institution, through the Principal Investigator and/or IRB as
appropriate, shall be responsible for informing subjects of the above important
information they learn from Company in accordance with the IRB-approved informed
consent form and Company shall not contact them. No other provision of this
Agreement shall be construed to override the provisions of this Section 2.1.

Clinical Trial Agreement
Page 2 of 19

<PAGE>

Section 3: Study Data/Results
-----------------------------

       3.1    Provision of Data/Results; Provision of Abstracts/Manuscripts].

       (a)    Institution shall own the data resulting from the Study.
Institution shall provide copies of the data produced in the performance of the
Study to Company. Company may use the Study data in accordance with Section 3.2.

       (b)    All data from laboratory analyses for Institution's Study subjects
which are performed off-site, and all other subject-specific data generated by
Company or its agents for Institution's Study subjects, if Institution does not
receive such data directly from the off-site laboratory or other source, shall
be provided by Company to Institution upon the Study Conclusion. If the Study is
blinded, Company shall also provide the randomization codes for Institution's
Study subjects upon the Study Conclusion.

       3.2    Use of Data/Results. Institution shall comply in all material
respects with all applicable federal, state and local laws and regulations
regarding the privacy of individually identifiable health information (including
its collection, use, storage, and disclosure), including, but not limited to,
the Health Insurance Portability and Accountability Act of 1996 ("HIP AA") and
the regulations promulgated thereunder, as may be amended from time to time.
Company agrees to collect, use, store, and disclose individually identifiable
health information collected or produced in the Study only for the purpose of
the Study and related studies (that is, other studies of the Study Drug, alone
or in combination with other drugs, or other studies that relate to the medical
condition or disease area under investigation in the Study), and for the purpose
of complying with applicable law, provided that all such uses are disclosed in
the IRB-approved informed consent form. If Institution's IRB-approved informed
consent form so states, Company may use information that is not identifiable
under any applicable U.S. laws for any research and development purpose. Company
will use all reasonable efforts to protect the privacy and security of
individually identifiable health information and will require its business
partners to do so also. Company will not contact any Study subjects, unless
permitted by the informed consent form. No other provision in this Agreement
shall be construed to override the provisions of this Section 3.2.

       3.3    Use of Specimens/Tissue. Company will collect, use, store, and
disclose any specimens/tissue it receives only in accordance with the Protocol
and informed consent form, and in any event will not collect, use, store, or
disclose any individually identifiable health information attached to or
contained within the specimens/tissue in any manner that would violate Section
3.2 of this Agreement.

Section 4: Publication
----------------------

       4.1    Principal Investigator shall be free to publish the data/results
from the Study in accordance with this Section 4.1.] Principal Investigator
shall be free to publish the data/results of the Study subject only to the
provisions of Section 8 regarding Company's Proprietary

Clinical Trial Agreement
Page 3 of 19

<PAGE>

Information. The Institution shall require Principal Investigator to furnish
Company with a copy of any proposed publication prior to submission for
publication, at least thirty (30) days prior to submission for manuscripts and
at least seven (7) days prior to submission for abstracts. Company shall be
entitled to review such proposed publications solely for the purpose of
identifying Company Proprietary Information, which shall be removed from the
publication upon Company's request; and to identify any patentable Inventions,
which shall be addressed as described below; and to provide any other comments
Company desires to provide, provided that Principal Investigator shall have no
obligation to address any such additional comments. At the expiration of such
thirty (30) day or seven (7) day period, Principal Investigator may proceed with
submission for publication provided that any identified Company Proprietary
Information has been removed; and provided further that upon notice by Company
that Company reasonably believes a patent application claiming an Invention (as
defined in Section 5) should be filed prior to such publication, in
Institution's discretion such submission shall be delayed for up to an
additional thirty (30) days or until any patent application or applications have
been filed, whichever shall first occur. In no event shall the submission of
such publication of results be delayed for more than sixty (60) days for
manuscripts and for more than thirty-seven (37) days for abstracts from the date
such proposed publication was provided to Company; at the end of said sixty (60)
or thirty-seven (37) days, the Principal Investigator shall be free to publish
such results as proposed.

Section 5: Inventions/Intellectual Property
-------------------------------------------

       5.1    The Principal Investigator and any other investigators
(hereinafter "Institution Investigator") who shall conceive and reduce to
practice an invention, solely or jointly, in the performance of the Study as
outlined in the Protocol (hereinafter referred to as "Invention") shall promptly
report such Invention to Institution and shall assign all of his or her rights,
title and interest in the Invention to Institution. Institution shall promptly
advise Company in writing of each Invention disclosed to Institution and shall
discuss with Company whether a patent application or applications (hereinafter
referred to, together with any patents issued thereon, as "Patent Rights")
pertaining to such Invention should be filed and in which countries. In the
event of joint inventorship between Company personnel and Institution
Investigator, Company personnel shall assign all of their rights, title and
interest in the Invention ("Joint Invention") to Company, and Institution
Investigator shall assign all of their rights, title and interest in the Joint
Invention to Institution, and the Joint Invention will be deemed to be jointly
owned. If both parties mutually agree that Patent Rights should be filed,
applications assigned solely to Institution shall be filed by Institution, and
applications owned jointly by Institution and Company shall be filed as mutually
agreed upon by the parties. In the event Company is not interested in having
Patent Rights filed with respect to a particular Invention, Company shall advise
Institution of such fact within ninety (90) days from the date on which the
Invention was disclosed to Company by Institution and Institution shall be free
to file and prosecute Patent Rights on such Invention (including Institution's
rights in any Joint Invention) at its own expense and to license such Patent
Rights to any other party.

       5.2    All patent costs pertaining to any Patent Rights filed by mutual
agreement of Company and Institution, including preparation, filing,
prosecution, issuance and maintenance costs, shall be borne by Company.

Clinical Trial Agreement
Page 4 of 19

<PAGE>

       5.3    As to any Patent Rights assigned in whole or in part to
Institution and filed by mutual agreement of the parties, Company shall have for
the three (3) months next following the filing of such Patent Rights in the
United States Patent and Trademark Office the option to negotiate a world-wide,
royalty bearing, exclusive license under the rights assigned by an Institution
Investigator to Institution therein with the right to sublicense. It is
understood that Institution will reserve the right to use any Invention for
research, clinical and educational purposes, and that if federal funding has
supported the Invention, Company's license will be subject to the rights,
conditions and limitations imposed by United States law with respect to Subject
Inventions (as defined in 35 U.S.C. Section 202 et seq., as amended), including
without limitation the royalty-free non-exclusive license granted to the United
States Government with respect to such Subject Inventions (see 35 USC Section
202 et seq., as amended, and regulations pertaining thereto).

       5.4    This option is to be exercised by written notice to Institution
during said three month period and the negotiation, during the three (3) months
next following such notice, of a license agreement containing license terms
standard for agreements between universities and industry including without
limitation clauses providing for payment of reasonable royalties and other
compensation to Institution, objective, time-limited due diligence provisions
for the development, commercialization and marketing of a product embodying the
Invention and product liability indemnification and insurance requirements which
are acceptable to Institution's liability insurance carrier. In the absence of
such notice by Company and agreement on license terms, Institution may grant a
license to such Patent Rights to any other party.

       5.5    All information given to Company by Institution in accordance with
Sections 5.1, 5.2, 5.3, and 5.4 will be held in confidence by Company so long as
such information remains unpublished or publicly undisclosed by Institution.

Section 6: Use of Name
----------------------

       6.1    Except for disclosure by Institution of Company's support for the
Study in publications, for purposes of recruitment/consent of Study subjects,
and by either Party for purposes of meeting any applicable requirements for the
registration of the Study or of Study results with a publicly accessible or
other clinical trial registry, and for satisfying the Company's obligation to
report its financial commitments to Institution in cash or in kind and related
material events in an 8K filed with the Securities and Exchange Commission
within four days of the date this Agreement is executed, neither Party to this
Agreement shall use the name of the other Party or of any staff member,
employee, student, or agent of the other Party or any adaptation, acronym or
name by which the other Party is commonly known, in any advertising, promotional
or sales literature or in any publicity without the prior written approval of
the Party or individual whose name is to be used., which approval shall not be
unreasonably withheld.

Section 7: Study Records
------------------------

       7.1    Institution shall make Study records (including minimum necessary
portions of

Clinical Trial Agreement
Page 5 of l9

<PAGE>

medical records) available to Company representatives upon reasonable request
for comparison with case report forms. Any audits conducted by Company will be
undertaken in conjunction with Institution, at reasonable times and with
reasonable prior notice, and pursuant to guidelines established by Institution
in order to assure patient confidentiality. Each of Company and Institution
shall retain records of the Study, including in Institution's case either the
original or a copy of all volunteer consent forms, in conformance with federal
regulations applicable to it. . Institution shall also make such records
available upon request for review by representatives of the U.S. Food and Drug
Administration. Company acknowledges that Company may not direct the manner in
which Institution fulfills its obligations to permit inspection by governmental
entities. It shall not be a breach of this Agreement for Institution to comply
with the demands and requests of any governmental entity in accordance with
Institution's judgment or to fail to inform and consult with the Company before
complying with such demand or request.

Section 8: Proprietary Information
----------------------------------

It is anticipated that in the performance of this Agreement, Principal
Investigator, Company and Institution may need to disclose to each other
information, which is considered confidential. The rights and obligations of the
parties with respect to such information are as follows:

       8.1    "Disclosing Party" shall mean a party that discloses Proprietary
Information (as defined in paragraph 8.2 below) under this Agreement. "Receiving
Party" shall mean a party that receives Proprietary Information under this
Agreement.

       8.2    "Proprietary Information" refers to information of any kind, other
than data from or results of the Study, which is obtained by Receiving Party
from Disclosing Party, which, by appropriate marking, is identified as
confidential and proprietary at the time of disclosure. In the event that
Proprietary Information must be provided visually or orally, obligations of
confidence shall attach only to that information which is confirmed by
Disclosing Party in writing within thirty (30) working days as being
confidential.

       8.3    Period of Restriction. For a period of five (5) years after the
Effective Date of this Agreement and indefinitely with respect to any
individually identifiable health information, institutional billing information
and institutional financial information disclosed by Institution to Company,
Receiving Party agrees to use reasonable efforts, no less than the protection
given their own confidential information, to use Proprietary Information
received from Disclosing Party and accepted by Receiving Party only in
accordance with this Section 8.

       8.4    Use of Proprietary Information. Receiving Party agrees to use
Disclosing Party's Proprietary Information solely for the purposes of conducting
the Study, obtaining any required review of the Study or its conduct, or
ensuring proper medical treatment of any patient or subject. Receiving Party
agrees to make Proprietary Information available only to those personnel and
agents at Receiving Party and those consultants and vendors who require access
to it in the performance of this Study and to inform them of the confidential
nature of such information.

       8.5    Release of Proprietary Information. Except as provided herein,
Receiving Party

Clinical Trial Agreement
Page 6 of 19

<PAGE>

agrees to keep all Proprietary Information confidential unless Disclosing Party
gives specific written consent for release.

       8.6    Notice of Unauthorized Disclosure. Receiving Party shall notify,
and shall require any recipient to notify, Disclosing Party of any disclosure
not authorized hereunder of which it becomes aware. In such situations,
Receiving Party shall take and shall require each such recipient to take
reasonable steps to prevent any further disclosure or unauthorized use.

       8.7    Exclusions. No Receiving Party shall be required to treat any
information as Proprietary Information under this Agreement in the event:

       (i)    it is publicly available prior to the date of the Agreement or
              becomes publicly available thereafter through no wrongful act of
              Receiving Party;

       (ii)   it was known to Receiving Party prior to the date of disclosure or
              becomes known to Receiving Party thereafter from a third party
              having an apparent bona tide right to disclose the information;

       (iii)  it is disclosed by Receiving Party in accordance with the terms of
              Disclosing Party's prior written approval;

       (iv)   it is disclosed by Disclosing Party without restriction on further
              disclosure;

       (v)    it is independently developed by Receiving Party; or,

       (vi)   Receiving Party is obligated to produce it pursuant to a
              requirement of applicable law or an order of a court of competent
              jurisdiction or a facially valid administrative, Congressional or
              other subpoena, provided that the Receiving Party, subject to the
              requirement or order or subpoena (A) promptly notifies Disclosing
              Party and (B) cooperates reasonably with Disclosing Party's
              efforts to contest or limit the scope of such disclosure.

       8.8    Each party reserves the right, in its sole discretion and without
prior notice to any other party, to disclose its own Proprietary Information to
any third party for any purpose.

Section 9: Budget and Payments
------------------------------

       9.1    General. Company agrees to support this Study with a research
grant of three hundred sixteen thousand seven hundred and fifty-five Dollars
($316,755.00), inclusive of indirect costs, 50% to be paid upon execution of
this Agreement, 25% to be paid by month three of the study, and 25% to be paid
by month six of the study, all subject to the internal-controls provisions of
the Sarbanes-Oxley Act.

       9.2    Checks. Checks shall be made payable to The General Hospital
Corporation, Federal Tax ID No.: 04-2697983, shall reference the name of the
Principal Investigator, the Protocol number, and the Research Management
agreement number 2009A055353, and shall be

Clinical Trial Agreement
Page 7 of 19

<PAGE>

forwarded to:

              Massachusetts General Hospital
              Research Finance
              PO Box 414876
              Boston, MA 02241-4876

       9.3    IRB Fee. Company shall pay a one-time, non-refundable,
non-overhead-bearing fee of twenty five hundred dollars ($2,500.00) to
Institution to cover its IRB's costs for reviewing the initial Protocol and any
subsequent annual reviews that may be required. Institution shall invoice
Company for this fee upon execution of this Agreement.

Section 10: Term and Termination
--------------------------------

       10.1   Term. The term of this Agreement shall be from the Effective Date
until completion of the Parties' substantive obligations under the Agreement in
the performance of the Study, unless earlier terminated in accordance with
Section

       10.2   Termination.

       (a)    Either Party hereto shall have the right to terminate the Study
and this Agreement at any time upon six (6) months prior written notice thereof
to the other Party, except that either Party may terminate the Study and this
Agreement at any time upon thirty (30) days prior written notice thereof to the
other Party in the event of a material breach of the Agreement by the other
Party, and except that either Party may terminate the Study and this Agreement
immediately upon written notice to the other Party if necessary to protect the
health, welfare or safety of any Study subject.

       (b)    If the Principal Investigator ceases to serve in such role during
the term of the Agreement, Institution shall promptly notify Company.
Institution may name a substitute principal investigator (who shall thereafter
be referred to as Principal Investigator for purposes of this Agreement),
subject to the approval of Company, which approval will not be unreasonably
withheld by the Company. If the Parties fail to reach agreement with respect to
continuation of the Study and the Agreement within ninety (90) days following
the date on which Institution notifies Company that the original Principal
Investigator became unavailable, Company shall have the right to terminate the
Study and this Agreement immediately upon written notice to Institution.

       10.3   Continuation of Enrolled Subjects. The Parties agree that if, at
the time either Party receives notice of termination pursuant to this section,
any subjects are enrolled in the Study, said subjects shall complete the Study,
at Company's expense, if completion is in the best interest of said subjects.

       10.4   Continuation of Grant/Payments. In the event of any termination
other than a for-

Clinical Trial Agreement
Page 8 of 19

<PAGE>

cause termination by Company for Institution's material breach, the amount of
the research grant by Company to support the Study shall be appropriately
prorated to allow Institution to recover reasonable costs and noncancellable
commitments incurred, including without limitation, termination salary costs of
any Institution personnel released as a result of such termination, and other
payments payable by Company for procedures or portions of procedures completed
at the time of termination shall be made/fulfilled.

       10.5   Survival. The obligations of the Parties under Sections 1.1
(Priority), 1.3, [1.4,] 2.1, 3.1, 3.2, 3.3, 4.1, 5.1-5.5, 6.1, 7.1, 8.1-8.8,
10.3, 10.4, 11.1, 11.2, 11.3, 12.1, 13.2, and 13A13.8 shall survive any
termination or expiration of this Agreement.

Section 11:  Subject Injury; Insurance; Coordination with Other Agreements
--------------------------------------------------------------------------

       11.1   Injury.

       (a)    Company agrees to reimburse Institution for (or otherwise pay for)
the care and treatment of any illness or injury occurring to a person involved
in the Study resulting from their participation in the Study.

       (b)    Company represents and warrants that it will not allow any Company
representative or agent to insert or negotiate into the Study's informed consent
form any language whatsoever.

       (c)    Company's commitment under (a) above shall not apply to any
illness or injury to the extent it directly results from: (i) the negligence or
reckless or intentional misconduct of, or violation of law by, Institution,
Principal Investigator, or Institution's personnel; or (ii) failure of
Institution, Principal Investigator, or Institution's personnel to adhere to the
terms of the Protocol for the Study, provided, however, that emergency medical
care shall not be deemed a violation of the Protocol.

       11.2   Insurance.

       (a)    Company shall, at its sole cost and expense, procure and maintain
policies of general liability insurance in amounts not less than Two Million
Dollars ($2,000,000) per occurrence and Two Million Dollars ($2,000,000) annual
aggregate covering its obligations under this Agreement, including contractual
liability coverage for injury under this Section 11, if any.

       (b)    Company shall provide Institution at its request with written
evidence of such insurance prior to the commencement of the Study. Company shall
provide Institution with written notice at least thirty (30) days prior to the
cancellation, non-renewal or material change, in such insurance; if Company docs
not obtain replacement insurance providing comparable coverage within such
thirty- (30-) day period, Institution shall have the right to terminate this
Agreement effective at the end of such thirty- (30-) day period without notice
of any additional waiting periods.

Clinical Trial Agreement
Page 9 of 19

<PAGE>

       11.3   Coordination with Other Agreements. The Parties do not intend any
provision in this Agreement concerning insurance commitments or indemnification
commitments (if any) to affect or be affected by any additional insurance or
indemnification commitments that may be provided for in any separate contract,
purchase order, terms and conditions document, or other agreement between the
Parties related to the Study (including agreements related to the purchase,
lease, or use of any Study Equipment).

Section 12: Notices
-------------------

       12.1   Any written notices, reports, correspondences or other
communications required under or pertaining to this Agreement shall be given by
prepaid, first class, registered or certified mail or by an express/overnight
delivery service provided by a commercial carrier, properly addressed as
follows:

              Jason McLaren, J.D., Pharm.D.
              Agreement Associate
              Partners Clinical Research Office
              101 Huntington Avenue, 4th Floor
              Boston, MA 02199

              Eric Rosenberg, M.D.
              Massachusetts General Hospital
              55 Fruit St.
              Boston, MA 02114

              Allen D. Allen
              CytoDyn, Inc.
              1511 Third Street
              Santa Fe, New Mexico 87505

Section 13: Miscellaneous
-------------------------

       13.1   Amendment. The terms of this Agreement can be modified only by a
writing, which is signed by authorized representatives of Institution and
Company.

       13.2   Choice of Law; Jurisdiction and Venue. This Agreement shall be
governed by and construed and interpreted in accordance with the laws of the
Commonwealth of Massachusetts. Each Party agrees to submit to the exclusive
jurisdiction of the Superior Court for Suffolk County, Massachusetts, and the
United States District Court for the District of Massachusetts with respect to
any claim, suit, or action in law or equity arising in any way out of this
Agreement or the subject matter hereof.

       13.3   Assignment. Neither Party to this Agreement may assign its
obligations hereunder without the prior written consent of the other Party.

Clinical Trial Agreement
Page 10 of 19

<PAGE>

       13.4   Entire Agreement. This Agreement, including any exhibits,
attachments, and other documents that are incorporated by reference herein,
constitutes the entire understanding and agreement between the Parties, and
supersedes and replaces all prior agreements, understandings, writings and
discussions between the Parties with respect to the subject matter of this
Agreement.

       13.5   Waiver. The failure of a Party in any instance to insist upon the
strict performance of the terms of this Agreement shall not be construed to be a
waiver or relinquishment of any of the terms of the Agreement, whether at the
time of the Party's failure to insist upon strict performance or at any time in
the future, and such term(s) shall continue in full force and effect.

       13.6   Severability. Each clause of this Agreement is a distinct and
severable clause and if any clause is deemed illegal, void, or unenforceable,
the validity, legality, or enforceability of any other clause of this Agreement
will not be affected thereby.

       13.7   Additional Partners HealthCare Hospital Site. In the event that an
additional Partners HealthCare hospital becomes an enrolling site for this
Study, then the Sponsor agrees that the substantive terms of the clinical trial
agreement with the additional Partners HealthCare hospital will be the same as
in this Agreement except with respect to budget and contracting party.

       13.8.  Titles. All the titles and headings contained in the Agreement are
inserted only as a matter of convenience and reference and do not define, limit,
extend, or describe the scope of this Agreement or the intent of any of its
provisions.

       13.9   Counterpart Signatures. This Agreement may be executed in one or
more counterparts, each of which counterpart shall be deemed an original
Agreement and all of which shall constitute but one Agreement.

       13.10  No Agency. Joint Venture or Partnership. Each Party's relationship
to the other Party under this Agreement will be that of an independent
contractor and neither Party shall be considered to be an agent, joint venturer
or partner of the other Party.

       IN WITNESS WHEREOF, the Parties have caused this Agreement to be duly
executed as of the Effective Date above written.

                           Signature page to follow.

Clinical Trial Agreement
Page 11 of l9

<PAGE>

CytoDyn, Inc.                                 THE GENERAL HOSPITAL
                                              CORPORATION

By: /s/  Allen D. Allen                       By:
   -------------------------                     -------------------------
Name: Allen D. Allen                          Name: Jason McLaren

Title: President and CEO                      Title: Agreement Assoc.

Date: September 28, 2009                      Date:
                                                   ----------------------

Read and Acknowledged:

----------------------------
By: ERIC S. ROSENBERG, MD
Date:

Clinical Trial Agreement
Page 12 of 19

<PAGE>

                                   EXHIBIT A

1.    PROTOCOL Protocol Summary

      1.1   Rationale
      In vivo studies using Cytolin, a monoclonal antibody that binds LFA1,
      suggested that Cytolin increases CD4+ T cell counts and decreases HIV
      viral load in HIV infected individuals. This study is a laboratory based
      pilot study to determine the immunologic mechanisms of action of this
      compound.

      1.2.  Hypothesis
      Cytolin preserves CD4+ T cell number and function in vitro by inhibiting
      CTL mediated killing of virus-specific CD4+ T helper cells.

      1.3.  Design
      This is an observational study that will enroll 10 HIV- and 10 HIV+
      individuals. Each subject will attend 3 study visits over a 6 month
      period. Laboratory studies testing the in vitro effects of Cytolin on T
      cell function and HIV replication will be done for each study visit.

2.    Study Objectives
      2.1.  Primary objective - determine the in vitro effect of Cytolin on CD4+
            and CD8+ T cell effector functions in HIV infected individuals.
      2.2.  Secondary objective - determine the in vitro effect of Cytolin on
            HIV replication.

3.    Introduction
      3.1.  Background
      One of the characteristic features of HI V infection is the progressive
      loss of CD4+ T cells. There arc likely several mechanisms by which CD4+ T
      cells are lost. One possibility is that these cells are killed by
      cytotoxic T lymphocytes 1. Since there are relatively few HIV infected
      CD4+ T cells, if CTL lysis is a major contributor to the loss of CD4+ T
      cells, then killing of both infected and uninfected CD4+ T cells would
      have to occur. It has been observed that CD8+ CTL from HIV infected
      individuals but not HIV seronegative controls lyse activated CD4+ T cells
      1. The mechanism of lysis appears to be MHC restricted, as HLA mismatched
      targets were not lysed. This means that C08+ CTL from HIV+ subjects
      recognized an unknown antigen normally presented via MHC class I on
      activated CD4+ T cells.

      Cytolin is a murine monoclonal antibody that binds to an epitope (also
      known as S6FI) on Lymphocyte Function-Associated Antigen I (LF Al )2. This
      epitope is preferentially expressed on cytolytic CD8+ T cells and appears
      to be induced following antigen specific activation. It is also present on
      null cells (such as NK cells) and infrequently on CD4+ T cells. CD8+ T
      cells expressing S6Fl have been shown to be elevated during the
      asymptomatic phase of HIV infection3. Furthemwre, the CD8+ T cells that
      kill HIV -infected cells are known to express the S6FI epitopc4-. Although
      some anti-LFAI antibodies have been shown to block cytolysis, anti-S6Fl
      antibodies do not appear to block this effector function 2.

      LFAI is an adhesion molecule expressed on T cells. Binding of LFA1 to ICAM
      on antigen presenting cells stabilizes the interaction between the cells
      allowing signaling through the T cell receptor. ICAM is also expressed on
      lymphocytes. During budding, HIV incorporates ICAM into its envelope.
      Transmission of HIV into uninfected T cells is facilitated by the LFA1 -
      rCAM interaction. Anti-LFA1 antibodies have been shown to inhibit
      cell-to-cell transmission of HIV. It is currently unknown whether Cytolin
      has this affect.

      Cytolin has been tested as a therapeutic in HIV infected individuals 5, 6.
      In pilot studies, Cytolin was shown to reduce HIV plasma viral load by
      0.5-1 log and increase relative CD4+ T cell counts. Since viral load and
      CD4+ T cell counts arc predictive of clinical progression, these results
      suggest that the use of Cytolin may delay disease progression.

      3.2.  Rationale

      This study is a laboratory based pilot study to test the hypothesis that
      Cytolin preserves CD4+ T cell number and function and decreases HIV
      replication in vitro. Cytolin has been administered on a compassionate use
      basis to HIV infected individuals. These studies suggested that Cytolin
      may increase CD4+ T cell counts and decrease HIV viral load in infected
      individuals. It is hypothesized that the increase in CD4+ T cell number is
      a result of

Clinical Trial Agreement

<PAGE>

      Cytolin inhibiting lysis of uninfected CD4+ T cells by CD8+ cytotoxic T
      Lymphocytes (CTL). It is currently unknown whether the increase in CD4+ T
      cell number also restores CD4+ T cell effector functions which are
      typically weak or absent in HIV infected individuals. The decline in viral
      load observed in subjects treated with Cytolin is thought to occur as a
      result of inhibiting transmission of the virus to uninfected cells by
      preventing the interaction of adhesion molecules that arc incorporated
      into the viral envelope with their ligands on target cells. However, this
      hypothesis is based on the use of other antibodies that bind LFA1. It is
      currently not known whether Cytolin has the same effect.

4.    Selection and Enrollment of Subjects
      4.1.  Inclusion Criteria
        o   Men and women age 18-65 years
        o   HIV seropositive - subjects identified with HIV infection defined by
            a positive HIV 1/2 ELISA and HIV-l Western Blot who do not meet
            criteria for antiretroviral therapy (viral load<100,000 copies/ml,
            CD4+>350 cells/ul).
        o   HIV seronegative - subjects identified as HIV uninfected defined by
            a nonreactive HIV 1/2 ELISA.
        o   Ability and willingness to give written informed consent.

      4.2.  Exclusion Criteria
        o   Presentation with an opportunistic infection or AIDS-defining
            illness.
        o   Receipt of investigational research agent within 30 days prior to
            study entry.
        o   Prior receipt of experimental HIV vaccine. Individuals who received
            a saline placebo are not excluded, provided they did not receive a
            sham vector or adjuvant.
        o   Receipt of immunosuppressive medications or immune modulators within
            the past six months. Individuals taking corticosteroid nasal spray
            for allergic rhinitis, topical steroids or over the counter
            medications for acute, uncomplicated dermatitis for a period no
            longer than 14 days will not be excluded.
        o   Active drug or alcohol use, dependence, or psychiatric illness that
            in the opinion of the study investigator would interfere with
            adherence to study protocol.
        o   Serious illness requiring hospitalization.

      4.3.  Study Enrollment Procedures
      This protocol and the informed consent will be reviewed and approved by
      the Massachusetts General Hospital/Partners Protection of Human Subjects
      Committee (MGH IRB) prior to implementation of the study. When an
      individual has been identified as a potential candidate for the study,
      study staff will explain the details of the study and obtain written
      informed consent.

5.    Study Treatment
      No treatment will be given to any subject enrolled in this study. If a
      subject becomes eligible for antiretroviral therapy, treatment can be
      initiated at the discretion of the subject and his/her health care
      provider. Subjects who initiate antiretroviral therapy may continue on the
      study.

6.    Clinical Evaluations
      6.1.  Schedule of events
      Three study visits are scheduled at 3 month intervals over the course of 6
      months. There will be a window period of +/- 7 days around the specific
      study date in which the subject will be allowed to participate in thc
      scheduled encounter. The date of all study visits will be determined at
      study entry.

------------------------------------------------------------------------------
         Evaluation                 Entry        3 month        6 month
------------------------------------------------------------------------------
  Medical History                     X
------------------------------------------------------------------------------
  Physical Exam/medications           X
------------------------------------------------------------------------------
  HIV ELISA and Western Blot          X
------------------------------------------------------------------------------
  CMV, EBV, VZV serology              X
------------------------------------------------------------------------------
  HLA typing                          X
------------------------------------------------------------------------------
  HIV RNA viral load                  X             X              X
------------------------------------------------------------------------------
  CD4+/CD8+ subsets                   X             X              X
------------------------------------------------------------------------------

Clinical Trial Agreement

<PAGE>

------------------------------------------------------------------------------
  Immunology studies                  X             X              X
------------------------------------------------------------------------------
  Virology studies                    X             X              X
------------------------------------------------------------------------------

      6.2.  Special Instructions and Definition of Evaluations

        o   A medical history must be present in source documents and completed
            prior to enrollment. The medical history should include any previous
            non-HIV related diagnoses of major organ systems.

        o   A medication history documenting any previous use of immune-based
            therapies, HIV -related vaccines, antiretroviral therapies must be
            obtained at study entry.

        o   A physical exam will be performed at study entry which includes
            determination of vital signs (temperature, pulse, blood pressure)
            and weight. Signs and symptoms of HI V-related and AIDS defining
            events will be documented. All confirmed and probable diagnoses made
            since the last study visit will be recorded in source documents.

        o   Enumeration of the absolute count and percentage of CD4+ and CD8+
            lymphocytes must be done by MGH clinical laboratory which is a CLIA
            certified clinical laboratory.

        o   Plasma HIV RNA will be performed using the Roche standard method by
            the MGH clinical laboratory which is CLIA and VQA certified.

        o   Class I HLA typing will be done.

        o   The plasma titer of antibodies to Cytomegalovirus, Epstein Bar
            virus, and Varicella Zoster virus will be determined.

        o   Laboratory studies - see section 8.

7.    Laboratory Studies
      7.1.  Primary Objective - determine the ill vitro effect of Cytolin on T
            cell number and effector functions in HIV infected individuals.
           7.1.1. To determine the effect of Cytolin on T cell number, PBMC
                  will be incubated in the presence and absence of Cytolin and
                  the frequency of CD4+ and CD8+ lymphocytes will be assessed
                  using flow cytometry. Since Cytolin is hypothesized to prevent
                  the lysis of activated CD4+ T cells, the cells will
                  additionally be stained with CD69, CD25, and CD38 to determine
                  if these cellular subsets arc preferentially maintained in
                  cultures which contain Cytolin. It has previously been shown
                  that CTL from HIV+ but not HIV- subjects lyse activated CD4+ T
                  cells. Therefore, thcsc experiments will be done using cells
                  from seropositive and seronegative donors. We anticipate that
                  Cytolin will have no significant effect on CD4+ T cell numbers
                  from HIV- subjects.
            7.1.2. Based on the currently available data it is unclear whether
                  Cytolin will block lytic activity of CTL. Furthermore, we arc
                  interested in whether Cytolin can block lysis of un infected
                  but not infected CD4+ T cells. To determine whether Cytolin
                  prevents lysis of target cells, infected CD4+ T cells will be
                  used as targets and autologous CD8+ T cells will be used as
                  effectors in a flow cytometry based cytotoxicity assay. In
                  this assay, targets are labeled with Cell Tracker Orange then
                  added to CD8+ effectors in the presence and absence of
                  CylOlin. Following incubation, target cell death is measured
                  by incorporation of 7AAD. Infected target cells will be
                  identified using an antibody to the HIV protein, p24. This
                  will allow us to determine the relative number of infected and
                  uninfected CD4+ T cells that arc lysed. We will also label
                  effector cells with antibodies against CDJ07a and granzymes to
                  correlate these effector molecules with lytic activity.
            7.1.3. Although S6F1 is preferentially expressed on cytolytic CD8+ T
                  cells, it has also been shown to be expressed on a
                  subpopulation of CD4+ T cells. The effect of Cytolin on CD4+ T
                  cells is currently unknown. To determine whether Cytolin binds
                  to CD4+ T cells, an aliquot of Cytolin will be conjugated to a
                  fluorophore then used to label CD8+ depleted PBMC. Cells will
                  also be stained with the activation markers CD25, CD69, CD38
                  and the cytolytic marker CDI07a. This will allow us to

Clinical Trial Agreement

<PAGE>

                  determine whether activated, cytolytic CD4+ T cells bind
                  Cytolin. These experiments will be performed on HIV+ and HIV-
                  subjects to determine whether the S6Fl epitope is
                  differentially regulated on CD4+ cells in HIV+ individuals.

            7.1.4. To determine the effect of Cytolin on CD4+ T cell functions
                  proliferation, cytokine secretion (IL2, TNFa, IFNg), and
                  expression of the co-stimulatory marker CD4+0L will be assess
                  in the presence and absence of Cytolin by flow cytometry. PBMC
                  or CD8+ depleted PBMC will be incubated with Cytolin then
                  stimulated with antigen (CMV, EBV, VZV, or HIV) to determine
                  the direct and indirect effects of Cytolin on CD4+ T cells.
                  Since CD4+ T cell function is typically weak or absent in HIV
                  infected individuals, these experiments will be performed on
                  HIV+ and HIV- subjects. This will allow us to determine
                  whether function can be restored in HIV+ subjects. Ifnot,
                  experiments using cells from the HIV- subjects may provide
                  insight into whether CD4+ T cell function is altered in any
                  way. If so, Cytolin may benefit HIV+ subjects who maintain
                  CD4+ T cell function as a result of being treated very early
                  during the course of their infection.

      7.2.  Secondary objective - determine the in vitro effect of Cytolin on
      HIV replication.

            7.2.1. Transmission of HI V from cell-to-cell is facilitated by
                  interactions between LFA1 and ICAM. Given that Cytolin reduced
                  viral loads in HIV infected individuals, we hypothesize that
                  Cytolin blocks this interaction. To test this hypothesis HIV
                  infected PHA blasts will be co-cultured with uninfected target
                  cells in the presence and absence of Cytolin and viral
                  replication will be determined using a p24 assay. These
                  experiments will be performed using cells from HIV- subjects.

            7.2.2. An alternative hypothesis is that infected cells are lysed
                  even the presence of Cytolin. Although this hypothesis is
                  being addressed as described in section 8.1.2, we will further
                  test this hypothesis by measuring the ability of CTL to
                  suppress HIV replication in the presence and absence of
                  Cytolin. In this assay, HIV infected CD4+ T cells are
                  co-cultured with autologous CD8+ T cells and viral replication
                  is monitored using a p24 ELISA. These experiments take into
                  account all CD8+ T cell effector functions, not just cell
                  killing. This approach may provide additional insight into the
                  mechanisms of action of Cytolin in vivo. These experiments
                  will be performed using cells from HIV+ and HIV - subjects.

8.    Statistical Considerations
      8.1.  General Design Issues
      The design of this study reflects the need to obtain blood from HIV+ and
      HIV- individuals in order to determine the in vitro effect of Cytolin on T
      cell function and HIV replication.
      8.2.  Sample Size Considerations
      Our experience with these type of experiments suggests that 10 HIV+ and JO
      HIV- subjects will be sufficient to extract meaningful results.

      8.3.  Enrollment and Accrual
      Based on the history of recruitment of subjects with HIV infection at the
      study site, it is anticipated that one to four subjects per month may be
      recruited. Thus it is expected that it will take one year to enroll all
      subjects.

      Experience at this site indicates that patients will likely show good
      adherence to the study visit schedule.

      8.4.  Monitoring
      Data completeness and quality will be monitored monthly by the laboratory
      manager and the study manager. Because of the small size and single site
      nature of the study it will be easy to examine the data for
      inconsistencies and missing data. Data will also be assessed for
      completeness and accuracy and inconstancies will be addressed with each
      research subject at the final study visit.

9.    Data Collection and Monitoring
      9.1.  Records to be kept
      At enrollment written informed consent will be obtained by study staff and
      recorded in the research chart. At each study visit, all clinical data
      including demographic data, HIV viral load, and T cell counts will be
      collected

Clinical Trial Agreement

<PAGE>

      using standardized forms created in advance specifically for this study.
      Data from these forms will be entered into a database within two weeks of
      the study visit. At study entry, retrospective HIV viral load, CD4+ and
      C08+ counts will be obtained from the subjects primary care physician if
      it is available.

      Subjects will not be identified by name on any forms, but rather by a
      patient identification number (PID) assigned by study staff at enrollment.
      The key to the identity of subjects will be maintained solely by the Study
      Coordinator.

      Research charts will be kept on site in a locked cabinet or room during
      the entire study period, which will end two months after the final study
      visit of the last enrolled subject. The study database will be password
      protected and only available to study staff.

      9.2.  Role of Data Management
      Eric S. Rosenberg, MD, principal investigator, is responsible for the
      Clinical Management Plan for this protocol at Massachusetts General
      Hospital.

      Sue Bazner, MSN NP, Study Coordinator, has been designated by Dr.
      Rosenberg to be responsible for the implementation of the Clinical Quality
      Management Plan.

      Jenna Rychert, PhD, Laboratory Coordinator, has been designated by Dr.
      Rosenberg to be responsible for the implementation of the Laboratory
      studies.

      9.3.  Clinical Site Monitoring and Record Availability
      This is a single site study and all monitoring will be conducted at the
      Massachusetts General Hospital. All study records will be kept in a locked
      cabinet.

10.   Human Subjects
      10.1  Institutional Review Board (IRB) review and Informed Consent
      This protocol and the informed consent document and any subsequent
      modifications will be reviewed and approved by the IRT or ethics committee
      responsible for oversight of the study. A signed consent form will be
      obtained from the subject. The consent fonn will describe the purpose of
      the study, the procedures to be followed, and the risks and benefits of
      participation. A copy of the signed consent will be given to the subject
      and documented in the research chart.

      10.2. Subject Confidentiality
      All laboratory specimens, evaluation forms, reports, and other records
      will be identified with the PID to maintain subject confidentiality. All
      records will be kept locked. All computer and networking programs will be
      done with coded numbers only. Clinical information will not be released
      without written permission of the subject, except when necessary for
      monitoring by IRB or the Office for Human Research Protections.

      10.3. Study Discontinuation
      The study may be discontinued at any time by the IRB or other government
      agencies as part of their duties to ensure the protection of research
      subjects.

11.   Biohazard Containment
Appropriate precautions to prevent the transmission of HIV and other blood-borne
pathogens will be undertaken in the drawing of blood, shipping and handling of
specimens, and all laboratory experiments.

12.   References

1.    Zarling 1M, Ledbetter JA, Sias J, et a1. HIV-infected humans, but not
      chimpanzees, have circulating cytotoxic T lymphocytes that lyse uninfected
      CD4+ cells. J Immunol. Apr 15 1990;144(8):2992-2998.
2.    Morimoto C. Rudd CE, Letvin NL, Schlossman SF. A novel epitope of the
      LFA-I antigen which can distinguish killer effector and suppressor cells
      in human CDS cells. Nature. Dee 3-9 1987;330(6147):479482.
3.    Cavallin F, Traldi A, Zambello R. Phenotypical and functional evaluation
      of CD8+/S6F 1+ T lymphocytes in haemophiliac individuals with HIV-I
      infection. Clin Exp Immunol. Jul 1993;93(1):51-55.

Clinical Trial Agreement

<PAGE>

4.    Tsubota H, Lord CI, Watkins Dr, Morimoto C, Letvin NL. A cytotoxic T
      lymphocyte inhibits acquired immunodeficiency syndrome virus replication
      in peripheral blood lymphocytes. J Exp Med. Apr 1 1989; 169(4): 1421-1434.

5.    Allen AD, Hart DN, Hechinger MK, Slattery MI, Chesson CV, 2nd, Vidikan P.
      Leukocyte adhesion molecules as a cofactor in AIDS: basic science and
      pilot study. Med Hypotheses. Aug 1995;45(2): 164-168.

6.    Allen AD, Hillis T, Vidikan P, Beer V. Pitfalls in the use of surrogate
      markers for human immunodeficiency virus disease: further evidence on
      pathogenesis. Med Hypotheses. Jul 1996;47(1):27-30.

Clinical Trial Agreement

<PAGE>

                                   EXHIBIT B

BUDGET AND PAYMENT SCHEDULE

Clinical Trial Agreement

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00163-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00163-of-00352.parquet"}]]